Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Luisa Carbognin

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

L. Carbognin1, I. Sperduti2, G. Arpino3, M.V. Dieci4, F. Schettini5, G. Griguolo6, M. Brunelli7, V. Guarneri8, R. Nortilli1, E. Fiorio9, S. Pilotto10, E. Orvieto11, E. Manfrin7, P. Conte6, S. de Placido3, G. Scambia12, G. Tortora10, E. Bria13

Author affiliations

  • 1 Medical Oncology, University of Verona, AOUI Verona, 37134 - Verona/IT
  • 2 Biostatistics, Regina Elena National Cancer Institute, Rome/IT
  • 3 Dipartimento Di Medicina Clinica E Chirurgia, AOU Policlinico Federico II, 80131 - Napoli/IT
  • 4 Medical Oncology 2, Istituto Oncologico Veneto IRCCS, 35128 - Padova/IT
  • 5 Dipartimento Di Medicina Clinica E Chirurgia, Azienda Universitaria Ospedaliera Federico II, 80131 - Napoli/IT
  • 6 Department Of Surgery, Oncology And Gastroenterology, University of Padova, Istituto Oncologico Veneto IRCCS, 35128 - Padova/IT
  • 7 Department Of Diagnostics And Public Health, Section Of Anatomical Pathology, University and Hospital Trust of Verona, Verona/IT
  • 8 Department Of Surgery, Oncology And Gastroenterology, Istituto Oncologico Veneto IRCCS, 35128 - Padova/IT
  • 9 Medical Oncology, AOU Integrata Verona, 37126 - Verona/IT
  • 10 Uoc Oncologia, Dipartimento Di Medicina, Università di Verona, Azienda Ospedaliera Universitaria Integrata, 37134 - Verona/IT
  • 11 Department Of Pathology, Istituto Oncologico Veneto IRCCS, 35128 - Padova/IT
  • 12 Department Of Woman And Child Health', Policlinico Universitario A. Gemelli I.R.C.C.S., 00168 - Roma/IT
  • 13 Uoc Oncologia Medica, Università Cattolica del Sacro Cuore - Fondazione Policlinico Universitario Agostino Gemelli, 00168 - Rome/IT
More

Resources

Abstract 4532

Background

Patients (pts) resected for luminal early breast cancer are assigned to receive aCT according to international guidelines based upon clinico-pathological features, regardless of the histotype, given the lack of prospective data for ILC. Thus, the magnitude of the benefit of the addition of aCT to aHT for ILC is still not sizable. The aim of this analysis was to investigate the effect of aCT in a multi-center series of luminal early stage pure ILC.

Methods

Clinico-pathological data of consecutive pts affected by luminal pure ILC, undergone surgery between 2000 and 2014, were correlated with disease-free and overall survival (DFS/OS) using a Cox model. A propensity score analysis was performed to evaluate the prognostic impact of aCT. Kaplan-Meier curves were compared with Log-Rank analysis.

Results

Data from 576 pts were gathered (median age 58 years (yrs)). At median follow-up of 72 months, 5-/10-yrs DFS and OS were 81.5%/71.8% and 91.8%/80.4%, respectively. Tumor-size according to TNM (T, HR 1.78, 95% CI 0.91-3.49, p = 0.09) and lymph-node (N) status (HR 2.97, 95% CI 1.69-5.19, p < 0.0001) were independent predictors for DFS at multivariate analysis. N status (HR 3.93, 95% CI 1.79-8.70, p = 0.001), Ki67 (HR 2.66, 95% CI 0.92-7.70, p = 0.072), and age (HR 2.32, 95% CI 1.09-4.93, p = 0.029) were predictors for OS. A significant prognostic effect of aCT upon OS was found after adjusting for T, N, Ki67, grading and age at diagnosis with the propensity score method, as shown in the table. Particularly, aCT significantly prolongs DFS in pts with T > 2 (p = 0.03) and OS in pts with Ki67 >4% (p < 0.0001).Table: 197P

OutcomeCategory5-yrs (%)10-yrs (%)Log-Rank
DFSaHT76.654.4p = 0.08
aCT + aHT85.076.4.
OSaHT80.955.6p = 0.001
aCT + aHT98.195.9

Conclusions

Despite the retrospective nature of this analysis, the propensity score analysis indicates that pts with luminal ILC may significantly benefit from the addition of aCT to aHT in terms of long-term survival, particularly for larger and more aggressive tumors.

Clinical trial identification

Legal entity responsible for the study

University of Verona.

Funding

University of Verona.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings